Yahoo Finance Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Chimerix (NASDAQ:CMRX) Full Year 2023 Results
Key Financial Results
Net loss: US$82.1m (down by 148% from US$172.2m profit in FY 2022).
US$0.93 loss per share (down from US$1.97 profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Chimerix EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 2.1%.
Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 2.1% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Chimerix has 2 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
